BNP Paribas Financial Markets
GRCE

BNP Paribas Financial Markets’s Grace Therapeutics GRCE Stock Holding History

BNP Paribas Financial Markets’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.9K Buy
7,100
+6,500
+1,083% +$25.5K ﹤0.01% 4907
2025
Q4 		$2.08K Buy
+600
New +$1.91K ﹤0.01% 5345

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

BNP Paribas Financial Markets's GRCE Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Grace Therapeutics (GRCE) stake by 1,083% in Q1 2026, buying an estimated $25.5K and bringing the position to 7,100 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4907.

BNP Paribas Financial Markets first reported a position in GRCE in Q4 2025 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

  • BNP Paribas Financial Markets held 7,100 shares of Grace Therapeutics worth $32.9K as of Q1 2026.
  • BNP Paribas Financial Markets bought 6,500 Grace Therapeutics shares in Q1 2026, an estimated $25.5K.
  • Grace Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4907 holding.
  • BNP Paribas Financial Markets first reported a position in Grace Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.